Loading viewer...
earnings
Format: PDF earnings
Arcus Biosciences presents its 2Q23 financial results and corporate updates on its late-stage oncology pipeline. The company showcases its productive R&D engine delivering 1-2 new development candidates annually, with multiple Phase 3 studies in lung and gastric cancers. Key partnerships with Gilead, Taiho, and AstraZeneca support commercialization of precision combination therapies targeting immuno-oncology and cell-intrinsic pathways.
earnings
35 Pages
American Electric Power Company
A.P. Møller-Mærsk Full Year Q4 2021 Results & Earnings
earningsearnings
58 Pages
A.P. Møller - Mærsk A/S
ASM International Q2 2023 Earnings Results
earningsearnings
40 Pages
ASM International